CA2666375A1 — 3-aminoimidazo[1,2-a]pyridine derivatives having an sglt1- and sglt2- inhibiting action for the treatment of type 1 and type 2 diabetes
Assigned to Merck Patent GmbH · Expires 2008-04-24 · 18y expired
What this patent protects
The invention relates to novel compounds of formula (1) wherein W, T, R1, R2, R3, R4, R5 and R6 have the designations cited in patent claim (1), said compounds being suitable for use as antidiabetic agents.
USPTO Abstract
The invention relates to novel compounds of formula (1) wherein W, T, R1, R2, R3, R4, R5 and R6 have the designations cited in patent claim (1), said compounds being suitable for use as antidiabetic agents.
Drugs covered by this patent
- Steglatro (ERTUGLIFLOZIN) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.